本帖最后由 老马 于 2012-1-13 21:20 编辑
! [; \, ]2 I7 O3 y5 M
2 I% w$ Q- Y" x5 L/ r# |% u0 P$ l' n爱必妥和阿瓦斯丁的比较4 |( a( z! |2 ]- n+ y
8 u) n) p# v, s
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/' U8 O- \. a5 \: d
1 Q* P' w9 ^$ V7 P8 {
! S. J( k; x: F4 k rhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
1 V- C p" P0 w==================================================! H. X' v+ N, D! D, q- f
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
0 i4 `) l" s! N- [! Q9 B# kPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
* f" V8 y5 u4 r/ x5 d4 y6 wResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported./ D& }# d: t- @
|